Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04622813
Other study ID # BIO-2020-0375
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 8, 2021
Est. completion date October 19, 2022

Study information

Verified date May 2023
Source American University of Beirut Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the effect of the addition of nefopam to a multimodal analgesic regimen consisting of ketoprofen and paracetamol during sevoflurane- dexmedetomidine-based anesthesia on postoperative morphine requirements in patients undergoing laparoscopic cholecystectomy.


Description:

Nefopam is a centrally-acting anti-nociceptive compound with supraspinal and spinal sites of action. It inhibits monoamine reuptake, modulates descending serotoninergic pain, and may also interact with a dopaminergic pathway. Because its mechanism of action is distinct from that of other analgesic opioids, nefopam may well have a role in analgesic protocols. The role of nefopam in multimodal analgesia has been extensively investigated in laparoscopic cholecystectomy. However, there is general agreement that more studies are needed to determine the ideal multimodal strategy. No previous study has investigated a combination regimen of the three most commonly prescribed non-opioid analgesics (NOA) (nefopam, ketoprofen, and paracetamol) vs ketoprofen and paracetamol combination during sevoflurane-dexmedetomidine based anesthesia on pain control after laparoscopic cholecystectomy. The aim of our study is to compare a combination regimen of three NOA (nefopam, ketoprofen, and paracetamol) vs ketoprofen and paracetamol combination during sevoflurane-dexmedetomidine based anesthesia on pain control after laparoscopic cholecystectomy. We will try to demonstrate the benefit with the addition of a third NOA, which is the nefopam, to the double-drug regimen including ketoprofen and paracetamol. Our hypothesis is that this combination regimen of three NOA is associated with less postoperative pain, less opioid consumption, shorter length of post-anesthesia care unit (PACU) stay, and fewer opioid-related adverse effects and postoperative complications compared to the double-drug regimen of ketoprofen and paracetamol. In this prospective randomized double-blind study, 90 patients aged 18 to 64 years, with American Society of Anesthesiologists (ASA) physical status I and II, will be randomly assigned using a computer-generated random number table to one of two treatment groups. Group A will receive sevoflurane-dexmedetomidine based anesthesia with ketoprofen and paracetamol for postoperative pain control, and group B will receive sevoflurane-dexmedetomidine based anesthesia with nefopam, ketoprofen, and paracetamol for postoperative pain control. The primary outcome measure of this study is total morphine consumption in PACU. Normally distributed data will be summarized as mean ± SD and non-normally distributed data will be summarized as median [interquartile range]. This study would have an impact on our current practice and may help find out the best multimodal analgesic strategy to control postoperative pain after laparoscopic cholecystectomy.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date October 19, 2022
Est. primary completion date October 19, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: - ASA physical status I-II - Age between 18 and 64 years - Patients able to give consent Exclusion Criteria: - ASA physical status III to V - History of chronic pain - Use of an opioid analgesic within 12 hours prior to surgery - Alcohol or drug abuse - Chronic opioid intake - Morbid obesity - Psychiatric disorder - Pregnancy or breast-feeding - Intolerance to NSAIDSs - Allergy or contraindication to nefopam (acute angle-closure glaucoma, epilepsy, coronary artery disease, prostate adenoma), to morphine or paracetamol (liver failure), to ketoprofen (increased risk of bleeding, stomach or intestinal ulcer, chronic kidney disease) or to dexmedetomidine (uncontrolled hypertension, heart block greater than first degree, or other clinically significant morbidities)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
nefopam, ketoprofen, paracetamol
Patients in this group will receive Nefopam and Ketoprofen in addition to the paracetamol intraoperatively prior to the anticipated end of the surgery
saline infusion, ketoprofen, paracetamol
Patients in this group will receive one placebo infusion (saline infusion) in addition to the ketoprofen and paracetamol intraoperatively prior to the anticipated end of the surgery

Locations

Country Name City State
Lebanon American University of Beirut Medical center Beirut

Sponsors (1)

Lead Sponsor Collaborator
American University of Beirut Medical Center

Country where clinical trial is conducted

Lebanon, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total morphine consumption in the post anesthesia care unit Total morphine doses consumed after the surgery during the post anesthesia care unit stay of the patient Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Total fentanyl Total fentanyl given intraoperatively. Intraoperatively
Secondary Total morphine Total morphine on the floor Throughout the patient's stay on the floor
Secondary Ketoprofen consumption Ketoprofen consumption on the floor Throughout the patient's stay on the floor
Secondary Paracetamol consumption Paracetamol consumption on the floor Throughout the patient's stay on the floor
Secondary Total morphine consumption at 24 hours after surgery Total morphine doses consumed at 24 hours after surgery 24 hours after surgery
Secondary Number of patients receiving morphine in PACU Number of patients receiving morphine in post anesthesia care unit Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Number of patients receiving morphine on the floor Number of patients receiving morphine on the floor Throughout the patient's stay on the floor
Secondary Number of patients receiving morphine during the first 24 hours after surgery Number of patients receiving morphine during the first 24 hours after surgery During the first 24 hours after surgery
Secondary Number of patients receiving ketoprofen on the floor Number of patients receiving ketoprofen on the floor On the floor
Secondary Number of patients receiving paracetamol on the floor Number of patients receiving paracetamol on the floor On the floor
Secondary NRS pain scores at rest in PACU NRS pain scores at rest in post anesthesia care unit Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary NRS pain scores at 24 h after surgery NRS pain scores at 24 hours after surgery 24 hours after surgery
Secondary sedation scores in PACU sedation scores in post anesthesia care unit Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Time to first morphine requirement Time to first morphine requirement From the time of arrival to PACU until discharge
Secondary Time to discharge (readiness) from PACU Time to discharge (readiness) from post anesthesia care unit Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Nausea and vomiting Incidence and severity of nausea and vomiting Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Rescue antiemetics Need for rescue antiemetics Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Pruritus Incidence of pruritus Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Respiratory depression Incidence of respiratory depression Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Urinary retention Incidence of urinary retention Throughout the patient's stay in the recovery room (average of 30 minutes after the surgery)
Secondary Tachycardia Episodes of tachycardia Intraoperatively and in PACU
Secondary Sweating Episodes of sweating Intraoperatively and in PACU
Secondary Quality of recovery Quality of recovery at 24 h using the QoR-40 At 24 hours after the surgery
Secondary Overall satisfaction score Overall satisfaction score collected one month after surgery. One month after surgery.
See also
  Status Clinical Trial Phase
Completed NCT05480111 - The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy Phase 4
Completed NCT06129305 - Erector Spina Muscle Distance From the Skin at Different Thoracal Elevations
Completed NCT04401826 - Micro-surgical Treatment of Gummy Smile N/A
Recruiting NCT04020133 - the Role of Popliteal Plexus Block in Pain Management After Anterior Cruciate Ligament Reconstruction. N/A
Completed NCT03023462 - Efficacy of an Anterior Quadratus Lumborum Block vs. a TAP-block for Inguinal Hernia Repair N/A
Completed NCT03652103 - Efficiency of Erector Spinae Plane Block For Patients Undergoing Percutaneous Nephrolithotomy Phase 4
Completed NCT03546738 - Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery N/A
Terminated NCT03261193 - ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain Phase 3
Withdrawn NCT03528343 - Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy Phase 1/Phase 2
Completed NCT02525133 - Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty Phase 3
Completed NCT03244540 - Regional Analgesia After Cesarean Section Phase 4
Enrolling by invitation NCT05316168 - Post Operative Pain Management for ACL Reconstruction Phase 3
Recruiting NCT04130464 - Intraperitoneal Infusion of Analgesic for Postoperative Pain Management Phase 4
Enrolling by invitation NCT04574791 - Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty N/A
Completed NCT04526236 - Influence of Aging on Perioperative Methadone Dosing Phase 4
Completed NCT04073069 - Scalp Infiltration With Diprospan Plus Ropivacaine for Postoperative Pain After Craniotomy in Adults Phase 4
Recruiting NCT05351229 - Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery Phase 4
Enrolling by invitation NCT05543109 - Ultrasound Guided Psoas Compartment Block vs Suprainguinal Fascia Iliaca Compartment Block N/A
Completed NCT05346588 - THRIVE Feasibility Trial Phase 3
Completed NCT04919317 - Combination Dexamethasone and Bupivacaine Pain Control in Reduction Mammaplasty Phase 2